Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study

被引：0
|
作者：
Piedra, A. [1 ]
Recio, S. Martinez [1 ]
Gonzalez, A. Hernandez [2 ]
Bueno, M. T. Moran [2 ]
Arriola, E. [3 ]
Recuero-Borau, J. [4 ]
Dols, M. Cobo [5 ]
Gonzalez, P. Cordeiro [6 ]
Martinez, J. Mosquera [7 ]
Garcia-Campelo, M. R. [7 ]
Blanco, A. Calles [8 ]
Alvarez, R. M. [8 ]
Garcia, M. Zapata [9 ]
Casado, M. D. Isla [9 ]
Perez, A. Callejo [10 ]
Gomez, P. Iranzo [10 ]
Joaquin, A. Barba [1 ]
Sullivan, I. G. [1 ]
Felip, E. [11 ]
Majem, M. [1 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[2] Hosp Badalona Germans Trias & Pujol, Dept Med Oncol, ICO Inst Catala Oncol Badalona, Badalona, Spain
[3] Hosp Mar CIBERONC, Dept Med Oncol, Barcelona, Spain
[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain
[5] Hosp Reg Univ Malaga Carlos Haya, Dept Med Oncol, Malaga, Spain
[6] Inst Invest Biomed Coruna INIBIC, Dept Med Oncol, La Coruna, Spain
[7] CHUAC Complexo Hosp Univ A Coruna, Dept Med Oncol, La Coruna, Spain
[8] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain
[9] Hosp Clin Univ Lozano Blesa, Dept Med Oncol, Zaragoza, Spain
[10] Vall Hebron Univ Hosp VHIO, Dept Med Oncol, Barcelona, Spain
[11] Vall Hebron Univ Hosp VHIO, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2507
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1476P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
    Rittberg, Rebekah
    Leung, Bonnie
    Shokoohi, Aria
    Pender, Alexandra
    Wong, Selina
    Al-Hashami, Zamzam
    Wang, Ying
    Ho, Cheryl
    CURRENT ONCOLOGY, 2023, 30 (06) : 5299 - 5308
  • [42] Long-term real- world outcomes of first-line (1L) pembrolizumab (pembro) monotherapy in PD-L1 ≥50% metastatic NSCLC.
    Velcheti, Vamsidhar
    Hu, Xiaohan
    Piperdi, Bilal
    Yang, Lingfeng
    Burke, Thomas A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression
    Ikezawa, Yasuyuki
    Mizugaki, Hidenori
    Morita, Ryo
    Tateishi, Kazunari
    Yokoo, Keiki
    Sumi, Toshiyuki
    Kikuchi, Hajime
    Kitamura, Yasuo
    Nakamura, Atsushi
    Kobayashi, Maki
    Aso, Mari
    Kimura, Nozomu
    Yoshiike, Fumiaki
    Furuta, Megumi
    Tanaka, Hisashi
    Sekikawa, Motoki
    Hachiya, Tsutomu
    Nakamura, Keiichi
    Shimokawa, Mototsugu
    Oizumi, Satoshi
    CANCER SCIENCE, 2022, 113 (06) : 2109 - 2117
  • [44] PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 < 50%: A multiomics approach.
    Garassino, Marina Chiara
    Proto, Claudia
    Dolezal, James M.
    Prelaj, Arsela
    Agnelli, Luca
    Triulzi, Tiziana
    Fabbri, Alessandra
    Ferrara, Roberto
    Sgambelluri, Francesco
    Torelli, Tommaso
    Brich, Silvia
    Manglaviti, Sara
    Anichini, Andrea
    Mortarini, Roberta
    Trinchieri, Giorgio
    Pruneri, Giancarlo
    De Braud, Filippo G.
    Torri, Valter
    Ganzinelli, Monica
    Lo Russo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression
    Kunimasa, Kei
    Nakamura, Harumi
    Nishino, Kazumi
    Nakatsuka, Shin-ichi
    Kumagai, Toru
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : E231 - E233
  • [46] Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore
    Tan, W. L.
    Huang, M.
    Chandwani, S.
    Hsu, T.
    Tan, S. C.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S630 - S630
  • [47] Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1
    Kilickap, S.
    Sezer, A.
    Ozguroglu, M.
    Gumus, M.
    Bondarenko, I.
    Gogishvili, M.
    Nechaeva, M.
    Schenker, M.
    Cicin, I.
    Fuang, H. G.
    Kulyaba, Y.
    Zyuhal, K.
    Scheusan, R. I.
    Baramidze, A.
    Garassino, M. C.
    Li, Y.
    Jia, X.
    Kaul, M.
    Perez, J.
    Seebach, F.
    Lowy, I.
    Pouliot, J. F.
    Kim, E.
    Rietschel, P.
    Magnan, H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S35 - S35
  • [48] PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
    Lo Russo, G.
    Sgambelluri, F.
    Prelaj, A.
    Galli, F.
    Manglaviti, S.
    Bottiglieri, A.
    Di Mauro, R. M.
    Ferrara, R.
    Galli, G.
    Signorelli, D.
    De Toma, A.
    Occhipinti, M.
    Brambilla, M.
    Rulli, E.
    Triulzi, T.
    Torelli, T.
    Agnelli, L.
    Brich, S.
    Martinetti, A.
    Dumitrascu, A. D.
    Torri, V
    Pruneri, G.
    Fabbri, A.
    de Braud, F.
    Anichini, A.
    Proto, C.
    Ganzinelli, M.
    Mortarini, R.
    Garassino, M. C.
    ESMO OPEN, 2022, 7 (06)
  • [49] Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience
    Hsu, Miles M.
    Xia, Yuhe
    Troxel, Andrea
    Delbeau, Daniela
    Francese, Kaitlyn
    Leis, Dayna
    Shepherd, Deneuve
    Balar, Arjun, V
    CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : E209 - E216
  • [50] Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer
    Shah, Mohsin
    Marmarelis, Melina E.
    Mamtani, Ronac
    Hennessy, Sean
    CLINICAL LUNG CANCER, 2022, 23 (08) : 731 - 736
12345